0001415889-11-000640.txt : 20110718 0001415889-11-000640.hdr.sgml : 20110718 20110718173002 ACCESSION NUMBER: 0001415889-11-000640 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110713 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20110718 DATE AS OF CHANGE: 20110718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Echo Therapeutics, Inc. CENTRAL INDEX KEY: 0001031927 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411649949 STATE OF INCORPORATION: DE FISCAL YEAR END: 0208 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35218 FILM NUMBER: 11972916 BUSINESS ADDRESS: STREET 1: 10 FORGE PARKWAY CITY: FRANKLIN STATE: MA ZIP: 02038 BUSINESS PHONE: 508 553-8850 MAIL ADDRESS: STREET 1: 10 FORGE PARKWAY CITY: FRANKLIN STATE: MA ZIP: 02038 FORMER COMPANY: FORMER CONFORMED NAME: SONTRA MEDICAL CORP DATE OF NAME CHANGE: 20020702 FORMER COMPANY: FORMER CONFORMED NAME: CHOICETEL COMMUNICATIONS INC/MN/ DATE OF NAME CHANGE: 20020701 FORMER COMPANY: FORMER CONFORMED NAME: SONTRA MEDICAL CORP DATE OF NAME CHANGE: 20020701 8-K 1 form8k-07182011_020717.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 13, 2011
 
Echo Therapeutics, Inc.
 (Exact name of Company as specified in its charter)
 
 
         
Delaware
  
000-23017
  
41-1649949
(State or other jurisdiction
of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer
Identification No.)
 
8 Penn Center
1628 JFK Blvd., Suite 300
Philadelphia, PA
  
 
 
19103
(Address of principal executive offices)
  
(Zip Code)
 
Company’s telephone number, including area code: (215) 717-4100
 
__________________________
 (Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

At our 2011 Annual Meeting of Shareholders (the “Annual Meeting”) held on July 13, 2011, the following matters were acted upon by our shareholders:

1.  
The election of two Class 1 directors and two Class 3 directors to the Company’s Board of Directors; and
 
2.  
The ratification of the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011.

As of May 16, 2011, there were 34,017,174 shares of common stock issued and outstanding.  The results of voting on each of the matters presented to shareholders at the Annual Meeting are set forth below:

   
VOTES
FOR
    
VOTES AGAINST / WITHHELD
    
ABSTENTIONS
    
BROKER
NON-VOTES
  
Election of directors:
                        
William F. Grieco (Class 1)
     14,790,914       159,920       —       10,772,003  
James F. Smith (Class 1)
     14,937,914       12,920       —       10,772,003  
Patrick T. Mooney, M.D. (Class 3)
     14,937,504       13,330       —       10,772,003  
Shawn K. Singh, J.D. (Class 3)
     14,790,904       159,930       —       10,772,003  
Ratification of Wolf & Company
     25,608,395       20,075       94,367       —  
 
Vincent D. Enright continues his term of office as a Class 2 director following the Annual Meeting.
 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                                                                                                         ECHO THERAPEUTICS, INC.
 
Dated:  July 18, 2011
                                                                                                        
By: /s/ Patrick T. Mooney              
Patrick T. Mooney
Chief Executive Officer and President